Association between antihypertensive medicine use and risk of ovarian cancer in women aged 50 years and older.

Adrenergic beta-antagonists Antihypertensive agents Calcium channel blockers Carcinoma, Ovarian epithelial Diuretics

Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 04 04 2023
revised: 06 08 2023
accepted: 10 08 2023
pubmed: 19 8 2023
medline: 19 8 2023
entrez: 18 8 2023
Statut: ppublish

Résumé

Epithelial ovarian cancer (EOC) has few modifiable risk factors. There is evidence that some antihypertensive medicines may have cancer preventive and/or therapeutic actions; therefore, we assessed the associations between use of different antihypertensive medicines and risk of specific EOC histotypes. Our nested case-control study of linked administrative health data included 6070 Australian women aged over 50 years diagnosed with EOC from 2004 to 2013, and 30,337 matched controls. We used multivariable conditional logistic regression to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between ever use of each antihypertensive medicine group, including beta-adrenergic blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, and alpha blockers, and the risk of EOC overall and separately for the serous, endometrioid, mucinous, clear cell and other histotypes. We found that most antihypertensive medicines were not associated with risk of EOC. However, women who used calcium channel blockers had a reduced risk of serous EOC (OR= 0.89, 95 % CI:0.81,0.98) and use of combination thiazide and potassium-sparing diuretics was associated with an increased risk of endometroid EOC (OR= 2.09, 95 % CI:1.15,3.82). Our results provide little support for a chemo-preventive role for most antihypertensives, however, the histotype-specific associations we found warrant further investigation.

Sections du résumé

BACKGROUND BACKGROUND
Epithelial ovarian cancer (EOC) has few modifiable risk factors. There is evidence that some antihypertensive medicines may have cancer preventive and/or therapeutic actions; therefore, we assessed the associations between use of different antihypertensive medicines and risk of specific EOC histotypes.
METHODS METHODS
Our nested case-control study of linked administrative health data included 6070 Australian women aged over 50 years diagnosed with EOC from 2004 to 2013, and 30,337 matched controls. We used multivariable conditional logistic regression to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between ever use of each antihypertensive medicine group, including beta-adrenergic blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, and alpha blockers, and the risk of EOC overall and separately for the serous, endometrioid, mucinous, clear cell and other histotypes.
RESULTS RESULTS
We found that most antihypertensive medicines were not associated with risk of EOC. However, women who used calcium channel blockers had a reduced risk of serous EOC (OR= 0.89, 95 % CI:0.81,0.98) and use of combination thiazide and potassium-sparing diuretics was associated with an increased risk of endometroid EOC (OR= 2.09, 95 % CI:1.15,3.82).
CONCLUSION CONCLUSIONS
Our results provide little support for a chemo-preventive role for most antihypertensives, however, the histotype-specific associations we found warrant further investigation.

Identifiants

DOI: 10.1016/j.canep.2023.102444 PMID: 37595337
pubmed: 37595337
pii: S1877-7821(23)00124-8
doi: 10.1016/j.canep.2023.102444
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102444

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest PW has received grant funding from AstraZeneca for an unrelated study of ovarian cancer and a speaker’s fee from AstraZeneca (November 2021). All other authors declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Auteurs

Karen M Tuesley (KM)

School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, Australia; Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: k.Tuesley@uq.edu.au.

Katrina Spilsbury (K)

Institute for Health Research, The University of Notre Dame Australia, Fremantle, Australia.

Penelope M Webb (PM)

School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, Australia; Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

Melinda M Protani (MM)

School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, Australia.

Suzanne Dixon-Suen (S)

Institute for Physical Activity and Nutrition, Deakin University, Geelong, Victoria, Australia; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia.

Sallie-Anne Pearson (SA)

School of Population Health, University of New South Wales, Sydney, Australia; Centre of Research Excellence in Medicines Intelligence, University of New South Wales, Sydney, Australia.

Peter Donovan (P)

Clinical Pharmacology Department, Royal Brisbane and Women's Hospital, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia.

Michael D Coory (MD)

Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.

Christopher B Steer (CB)

Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, Albury, Australia; University of NSW Rural Clinical School, Albury Campus, Albury, New South Wales, Australia.

Louise M Stewart (LM)

School of Population and Global Health, The University of Western Australia, Perth, Australia.

Nirmala Pandeya (N)

School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, Australia; Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

Susan J Jordan (SJ)

School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, Australia; Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

Classifications MeSH